Skip to main content Skip to section navigation Skip to footer
Avalo Therapeutics, Inc. Corporate Home
  • About
    • Overview
    • Leadership
    • Board of directors
    • Contact
  • Science
    • Overview
    • IL-1β in HS
    • IL-1β in CPPD
  • Pipeline
    • Overview
    • AVTX-009 for HS
    • AVTX-009 for CPPD
  • Patients
    • Our commitment
    • Clinical trials
    • Resources
    • Access to investigational therapies
  • Investors
    • Overview
    • News, events & presentations
    • Analyst coverage
    • Stock data
    • SEC filings
    • Corporate governance
    • IR resources
  • Careers
    • Overview
    • Values
    • Benefits
    • Job openings

Press Releases

News, events & presentations

News, events & presentations

  • Press Releases
  • Events
  • Presentations
  • Email alerts
Jul 20, 2016 9:52 am EDT
Cerecor Announces $1.0 Million Research & Development Grant from the National Institute on Alcohol Abuse and Alcoholism at the National Institutes of Health
May 16, 2016 9:10 am EDT
Cerecor Inc. Reports First Quarter 2016 Financial Results
Apr 11, 2016 9:10 am EDT
Cerecor Announces $1.0 Million Research & Development Grant from the National Institute on Drug Abuse (NIDA) at the National Institutes of Health
Mar 23, 2016 9:10 am EDT
Cerecor Inc. Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015
Mar 8, 2016 9:10 am EST
Cerecor Inc. to Present at the Roth Conference on March 16th
Feb 22, 2016 9:10 am EST
Cerecor to Host R&D Day in New York City on March 1, 2016
Feb 2, 2016 9:10 am EST
Cerecor Announces Initiation of Phase 2 Clinical Trial With CERC-501 for Smoking Cessation
Feb 1, 2016 9:10 am EST
Cerecor Inc. to Present at the BIO CEO & Investor Conference in New York City
Jan 19, 2016 9:10 am EST
Cerecor Announces Publication Describing Antidepressant Activity of CERC-301 in Preclinical Model
Jan 12, 2016 9:10 am EST
Cerecor Inc. Appoints Thomas Aasen to Board of Directors
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Next Pagearrow_forward
  • Contact IR
  • RSS
  • Email Alerts
  • Accessibility
    accessibility
610.254.4205
in
1500 Liberty Ridge Drive
Suite 321
Wayne, PA 19087
Avalo
PRIVACY POLICY DISCLAIMER
©2025 Avalo Therapeutics, Inc.